The level of minimal residual disease (MRD) is paramount to link the depth of response and long-term outcome. Recent advances in treatment demand a more sensitive response criteria which includes MRD evaluation. Therefore, MRD has been defined as one of the best surrogate markers to predict overall survival and accelerate the approval of new therapies in Multiple Myeloma (MM).
In this webinar, Mantas Radzevičius explain the experience with MM MRD in his clinical laboratory, from a theoretical and practical perspective.
